外源性皮质糖类的剂量依赖性和组织特异性不良影响:优化临床实践的见解
Riccardo Pofi1, Nantia Othonos1, Thomas Marjot1,2
1Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK.
Journal of endocrinological investigation
|July 7, 2025
概括
低至中等剂量的普雷迪尼索隆 (一种葡萄糖皮质类药物) 在不同组织中不同影响胰岛素敏感性. 脂肪组织对普雷迪尼索隆的反应是剂量依赖的,这突显了在葡萄糖皮质体治疗中选择剂量的重要性.
科学领域:
- 内分泌学 在内分泌学.
- 代谢医学是一种代谢医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 外源性葡萄糖皮质激素 (GCs) 已被广泛使用,但其剂量特定的代谢作用尚不清楚.
- 有限的数据存在于低到中等的GCs的不同组织特异性和剂量依赖性影响.
研究的目的:
- 调查低至中等剂量普得尼索隆对胰岛素敏感性的组织特异性和剂量依赖性影响.
- 评估普得尼索隆对健康个体骨代谢的影响.
主要方法:
- 一项对三项涉及30名健康男性志愿者的临床试验的后期综合分析.
- 每天服用10毫克,15毫克或20毫克的普雷迪尼索隆一周.
- 评估肝脏,肌肉和脂肪组织的胰岛素敏感性,使用高胰岛素-高血糖;评估骨质卡尔辛对骨的循环.
主要成果:
- 普雷迪尼索隆15毫克和20毫克同样降低了肝脏和骨肌肉中的胰岛素敏感性.
- 对脂肪组织胰岛素敏感性的有害影响是剂量依赖的.
- 在服用15毫克和20毫克普雷迪尼索隆后,骨质卡尔水平同样下降,没有显著的剂量影响.
结论:
- 普雷迪尼索隆诱导的胰岛素耐药性是组织特异和剂量依赖的.
- 每天15毫克普雷迪尼索隆7天诱导了临床相关的代谢变化.
- 脂肪组织对普得尼索隆的反应是可变的,这强调了在GC治疗中谨慎选择剂量.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Dose-Response Relationship: Selectivity and Specificity
8.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
8.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
398
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
398
Dose-Response Relationship: Overview
3.7K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.7K
Insulin: Dosing Regimen and Adverse Effects
265
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
265


